Carisma Therapeutics Valuation
| CARM Stock | 0.44 0.02 4.35% |
Carisma Therapeutics is undervalued. Carisma Therapeutics shows a prevailing Real Value of USD1.47 per share. The current price of the firm is USD0.44. Our model approximates the value of Carisma Therapeutics from analyzing the firm fundamentals such as Shares Outstanding of 41.75 M, operating margin of (3.88) %, and Return On Equity of -3.63 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Carisma Therapeutics' valuation include:
Price Book 114.0987 | Enterprise Value | Enterprise Value Ebitda (0.06) | Price Sales 0.9078 | Enterprise Value Revenue 0.4289 |
Undervalued
Today
Please note that Carisma Therapeutics' price fluctuation is extremely dangerous at this time. Calculation of the real value of Carisma Therapeutics is based on 3 months time horizon. Increasing Carisma Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Carisma stock is determined by what a typical buyer is willing to pay for full or partial control of Carisma Therapeutics. Since Carisma Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Carisma Stock. However, Carisma Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.44 | Real 1.47 | Target 4.57 | Hype 0.44 |
The intrinsic value of Carisma Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Carisma Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Carisma Therapeutics helps investors to forecast how Carisma stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Carisma Therapeutics more accurately as focusing exclusively on Carisma Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Carisma Therapeutics' intrinsic value based on its ongoing forecasts of Carisma Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Carisma Therapeutics' closest peers.
Carisma Therapeutics Cash |
|
Carisma Valuation Trend
Knowing Carisma Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Carisma Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Carisma Therapeutics Total Value Analysis
Carisma Therapeutics is currently projected to have valuation of (5.16 M) with market capitalization of 18.4 M, debt of 3.12 M, and cash on hands of . The negative valuation of Carisma Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Carisma Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(5.16 M) | 18.4 M | 3.12 M |
Carisma Therapeutics Investor Information
About 27.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.52. Carisma Therapeutics last dividend was issued on the 8th of March 2023. The entity had 1:20 split on the 8th of March 2023. Based on the key indicators related to Carisma Therapeutics' liquidity, profitability, solvency, and operating efficiency, Carisma Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February.Carisma Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Carisma Therapeutics has an asset utilization ratio of 16.66 percent. This suggests that the Company is making USD0.17 for each dollar of assets. An increasing asset utilization means that Carisma Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Carisma Therapeutics Ownership Allocation
Carisma Therapeutics holds a total of 41.75 Million outstanding shares. Carisma Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Carisma Therapeutics Profitability Analysis
The company reported the previous year's revenue of 14.92 M. Net Loss for the year was (86.88 M) with loss before overhead, payroll, taxes, and interest of (43.24 M).Carisma Therapeutics Past Distributions to stockholders
About Carisma Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Carisma Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Carisma Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Carisma Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Carisma Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Carisma Therapeutics. We calculate exposure to Carisma Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Carisma Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -53.3 M | -50.6 M | |
| Pretax Profit Margin | (5.24) | (5.50) | |
| Operating Profit Margin | (5.35) | (5.62) | |
| Net Loss | (5.24) | (5.50) | |
| Gross Profit Margin | (4.56) | (4.34) |
A single share of Carisma Therapeutics represents a small ownership stake in the entity. As a stockholder of Carisma, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
Carisma Therapeutics Dividends Analysis For Valuation
Please note that Carisma Therapeutics has scaled down on payment of dividends at this time. As of the 18th of January 2025, Price Earnings To Growth Ratio is likely to grow to 0.01, though Retained Earnings are likely to grow to (209.6 M).
There are various types of dividends Carisma Therapeutics can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Carisma shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Carisma Therapeutics directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Carisma pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Carisma Therapeutics by the value of the dividends paid out.
Carisma Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Carisma Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 33.5 M |
Carisma Therapeutics Current Valuation Indicators
Carisma Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Carisma Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Carisma Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Carisma Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Carisma Therapeutics' worth.When determining whether Carisma Therapeutics is a strong investment it is important to analyze Carisma Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Carisma Therapeutics' future performance. For an informed investment choice regarding Carisma Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Carisma Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Carisma Therapeutics. If investors know Carisma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Carisma Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share | Quarterly Revenue Growth (0.12) | Return On Assets | Return On Equity |
The market value of Carisma Therapeutics is measured differently than its book value, which is the value of Carisma that is recorded on the company's balance sheet. Investors also form their own opinion of Carisma Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Carisma Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Carisma Therapeutics' market value can be influenced by many factors that don't directly affect Carisma Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Carisma Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Carisma Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Carisma Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.